Fig. 6

The hypothesis of MyD88-dependent systemic and local pathogenic mechanisms in RA. MyD88 dimerization drives systemic and local inflammatory and destructive processes. ST2825 effectively targets systemic inflammation in RA PBMC and local RA SFs aggressiveness by inhibiting cell cycle progression, invasion, and production of inflammatory and pain mediators, promoting apoptosis, and likely restoring mitochondrial homeostasis